Abstract Library

#4441 Gastric neuroendocrine neoplasms in younger patients: A retrospective single-centre study

Introduction: Gastric neuroendocrine neoplasms (gNENs) are rare neoplasms arising from stomach enterochromaffin-like (ECL) cells. Type I gNENs are the most common type, typically indolent and arising in the context of chronic atrophic gastritis (CAG). While type I gNENs are generally diagnosed in pts over 50, their occurrence in younger pts raises concern about the onset of CAG-related complications at an earlier age, potentially affecting tumour growth and clinical outcomes. Young-oriented studies on type I gNETs are still lacking in literature.

Conference:

Presenting Author:

Authors: Romano E, Rinzivillo M, Marasco M, Dell' Unto E, Esposito G,

Keywords: Gastric neuroendocrine neoplasm, Young adults, Chronic Atrophic Gastritis,

#4437 Pancreatic metastases in neuroendocrine neoplasia: A systematic review

Introduction: Neuroendocrine neoplasias (NENs) are a heterogeneous group of neoplasms that often metastasise to distant organs, with the liver and bones as common targets. However, metastases to the pancreas are uncommon, accounting for 2–5% of pancreatic malignancies.

Conference:

Presenting Author:

Authors: Rinzivillo M, Romano E, Dell' Unto E, Marasco M, Panzuto F,

Keywords: pancreatic metastasis, 68Gallium-PET, incidence,

#4171 Prevalence of sarcopenia in patients with advanced intestinal neuroendocrine neoplasms at time of diagnosis

Introduction: Sarcopenia is defined as the loss of muscle mass, strength, and physical performance. First-line therapy for NENs includes somatostatin analogues (SSAs), which could be responsible for malabsorption conditions (e.g. exocrine pancreatic insufficiency - EPI), that can affect clinical outcomes and treatment response. However, the relationship between sarcopenia and NENs is still lacking in the literature.

Conference:

Presenting Author: Marasco M

Authors: Romano E, Polici M, Lerose F, Marasco M, Nardacci S,

Keywords: malnutrition, sarcopenia, somatostatin analogues, exocrine pancreatic insufficiency,

#2159 Hepatic Steatosis Secondary to Peptide Receptor Radionuclide Therapy with Somatostatin Analogue

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177-Lutetium-DOTA-TATE is a therapeutic modality for neuroendocrine tumors. It has some well known side effects, concerning specially the bone marrow (from cytopenias to myelodysplastic syndrome), in addition to mild renal effects. Hepatotoxicity from PRRT is still being studied.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Matheos de Lima B

Authors: Arruda Matheos de Lima B, Gonçalves R, Romano Gaspar P, Linhares Riello de Mello E, Oliveira Albagli R,

Keywords: peptide receptor radionuclide therapy, lutetium, collateral effects, hepatotoxicity, neuroendocrine tumor, hepatic steatosis,

#2091 Differential Signalling Pathways Drive Therapeutic Resistance in Neuroendocrine Tumors

Introduction: Most of the current therapeutic strategies used for neuroendocrine tumors (NETs) are insufficient due to poor knowledge of these tumours. Despite showing differentiated features, NETs often exhibit therapeutic resistance to common treatments similarly to other cancers. Although signalling abnormalities have been reported, molecular mechanisms responsible for this resistance phenomenon are yet to be understood.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Romano D, Gerard C, Poizat F, Niccoli P, Barlier A,

Keywords: neuroendocrine tumors, drug resistance, proteomics, kinases, apoptosis,